ERBB2 and breast cancer: The most recent clinical guidelines for HER2+ BC therapy recommend the combination of dual HER2 blockade, with antibodies trastuzumab and pertuzumab, and taxane-based chemotherapy as the first line treatment for metastatic cases (128) and for early-stage cases in the neoadjuvant setting (129).